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Killer cell immunoglobulin-like receptors (KIR) regulate the activity of natural killer (NK) cells
and have been shown to be associated with susceptibility to a number of human infec-
tious diseases. Here, we analyzed NK cell function and genetic associations in a cohort
of 52 rhesus macaques experimentally infected with SIVmac and subsequently stratified
into high viral load (HVL) and low viral load (LVL) plasma viral loads at set point. This strat-
ification coincided with fast (HVL) and slow (LVL) disease progression indicated by the
disease course and critical clinical parameters including CD4+ T cell counts. HVL animals
revealed sustained proliferation of NK cells but distinct loss of peripheral blood NK cell
numbers and lytic function. Genetic analyses revealed that KIR genes 3DL05, 3DS05, and
3DL10 as well as 3DSW08, 3DLW03, and 3DSW09 are correlated, most likely due to under-
lying haplotypes. SIV-infection outcome associated with presence of transcripts for two
inhibitory KIR genes (KIR3DL02, KIR3DL10) and three activating KIR genes (KIR3DSW08,
KIR3DS02, KIR3DS05 ). Presence of KIR3DL02 and KIR3DSW08 was associated with LVL
outcome, whereas presence of KIR3DS02 was associated with HVL outcome. Further-
more, we identified epistasis between KIR and MHC class I alleles as the transcript
presence of the correlated genes KIR3DL05, KIR3DS05, and KIR3DL10 increased HVL
risk when Mamu-B*012 transcripts were also present or when Mamu-A1*001 transcripts
were absent. These genetic associations were mirrored by changes in the numbers, the
level of proliferation, and lytic capabilities of NK cells as well as overall survival time and
gastro-intestinal tissue viral load.
Keywords: virus infection, killer cell immunoglobulin-like receptors, MHC class I ligands, genetic polymorphism,
epistasis, rhesus macaque SIV infection model, AIDS
INTRODUCTION
Natural killer (NK) cells are large bone marrow-derived granu-
lar lymphocytes that perform essential functions in the innate
immune response against various pathogens and in the prim-
ing of adaptive immunity. The main effector functions of NK
cells are target cell killing and cytokine release, which are reg-
ulated via integration of signals derived from stimulatory and
inhibitory receptors expressed on the cell surface of these lym-
phocytes. NK cells are important effector cells to combat infection
with viruses (1), including human and simian immunodeficiency
viruses (SIVs) (2–4).
Killer cell immunoglobulin-like receptors (KIR) are crucial
regulators of NK cell activity and exhibit considerable allelic poly-
morphism and copy-number variations in humans and higher
primates (5, 6). Epidemiological studies of human immunode-
ficiency virus 1 (HIV-1) infection indicate that a combination
of HLA-Bw4-80I with either KIR3DL1 or KIR3DS1 is associ-
ated with delayed progression to AIDS (3, 7–9). Differences in
expression levels of KIR3DL1 allotypes correlate with different
functional capacities of NK cells (10), and KIR3DL1 allotypes
expressed at high levels are associated with delayed progression
to AIDS (11). While the role of inhibitory KIR3DL1 in the regula-
tion of NK cell activity toward HIV-1-infected cells is plausible,
the molecular basis underlying the epistasis of KIR3DS1 with
HLA-Bw4-80I is unknown and any demonstration of physical
interaction between KIR3DS1 and HLA-Bw4 proteins has so far
been unsuccessful. Nevertheless, KIR3DS1-positive NK cells were
reported to inhibit HIV-1 replication more effectively on target
cells expressing HLA-Bw4-80I compared to KIR3DS1-negative NK
cells (12). In addition, both KIR3DS1- and KIR3DL1-positive NK
cell proportions are elevated during acute HIV-1 infection in the
presence of HLA-Bw4-80I molecules (13). A recent paper by Song
and colleagues (9) confirmed these findings and demonstrated
the impact of the strength of educational signals obtained via the
KIR3DL1 receptor and an important role of CC-chemokine release
to inhibit HIV-1 replication. Further support for the impact of
NK cells on HIV-1 infection was documented in studies of HIV-
1 peptide escape mutations that resulted in stronger interaction
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of the inhibitory KIR2DL2 with HLA-C1 presenting mutated
peptides (14).
Simian immunodeficiency virus (SIV)-infected rhesus macaques
represent an established and important animal model to study
the mechanisms of HIV infection. SIV-induced syndromes and
the temporally diverse progression to AIDS of SIV-infected rhe-
sus macaques are remarkably similar to human HIV-1 infection
with variable disease outcome ranging from spontaneous con-
trol of plasma viremia (elite controllers, about 5–20% of infected
individuals) to uncontrolled viremia and rapid disease course (fast
progressors,about 5–10%). These polarized clinical outcomes dur-
ing persistent viremia in experimentally infected rhesus macaques
suggest genetic variability may play a critical role in SIV contain-
ment. Rhesus macaque KIR genes are considered as candidate
genes that contribute to different clinical outcomes as they are
at least as diverse as human KIR genes (15–18). Indeed, in SIV-
infected rhesus macaques, copy number variations (CNV) of the
inhibitory KIR3DL05 gene were shown to be associated with fast
progression to AIDS, whereas CNVs of activating KIR3DS genes
were associated with control of virus replication (19, 20). How-
ever, it is clear that the studies of the beneficial or detrimental
combinations of KIR and MHC class I polymorphisms are in their
infancy and much has yet to be learnt about these associations.
Further, it is unclear whether changes in the level of expression of
KIRs occur during the course of SIV infection and whether these
changes contribute to disease pathogenesis.
Herein, we demonstrate that NK cells in SIV-infected rhe-
sus macaques with rapid disease progression and high viral load
(HVL) show sustained proliferation but less lytic activity, followed
by a dramatic depletion of NK cells from the peripheral blood.
This functional impairment is accompanied by changes of tran-
scription of five KIR genes (inhibitory: KIR3DL02, KIR3DL10;
activating: KIR3DSW08, KIR3DS02, KIR3DS05). Presence of the
correlated KIR3DL05, KIR3DS05, and KIR3DL10, genes combined
with presence of Mamu-B*012 or with lack of Mamu-A1*001
was more frequently found in animals rapidly progressing to
disease, and animals with such KIR/MHC class I combinations dis-
played higher gastro-intestinal tissue (GIT) viral loads and shorter
survival times.
MATERIALS AND METHODS
ETHICAL STATEMENT
Juvenile to adult male rhesus macaques (Macaca mulatta) of
Indian origin were used for the studies reported herein. All ani-
mals were born and maintained at the Yerkes National Primate
Research Center of Emory University (Atlanta, GA, USA) in accor-
dance with the regulations of the Committee on the Care and
Use of Laboratory Animal Resources, National Research Coun-
cil and the Department of Health and Human Service guideline
titled Guide for the Care and Use of Laboratory Animals, and
with the Weatherall report (21). None of the animals, blood
and tissue samples originated from the German Primate Center.
The animals were fed monkey diet (Purina) supplemented daily
with fresh fruit or vegetables and water ad libitum. Additional
enrichment including the delivery of appropriate safe toys is pro-
vided and overseen by the Yerkes enrichment staff and animal
health is monitored daily by the animal care staff and veterinary
personnel, available 24/7. Monkeys are caged in socially compati-
ble same sex pairs to facilitate social enhancement and well-being.
Monkeys showing signs of sustained weight loss, disease or dis-
tress are subject to clinical diagnosis based on symptoms and
then provided either standard dietary supplementation analgesics
and/or chemotherapy. Monkeys whose symptoms cannot be alle-
viated using standard dietary supplementation, analgesics and/or
chemotherapy were humanely euthanized using an overdose of
barbiturates according to the guidelines of the American Veteri-
nary Medical Association. The studies reported herein were per-
formed under IACUC protocol #2001186“Innate immunity in SIV
infection” which was reviewed and approved by the Emory Uni-
versity IACUC. It has been assigned the IACUC protocol number
“YER-2001186-082414GA.”The Yerkes National Primate Research
Center has been fully accredited by the Association for Assess-
ment and Accreditation of Laboratory Animal Care International
since 1985. All experiments were reviewed and approved by the
Emory institutional animal use and care as well as biosafety review
Committees.
SIV INFECTION OF RHESUS MACAQUES
This study was conducted on a cohort of 52 juvenile to adult
male rhesus macaques that were infected intravenously with 1000
TCID50 of either SIVmac251 (n= 5) or SIVmac239 (n= 47)
grown in con-A blast cultures from normal rhesus macaques.
Statistical analyses in this report results were fairly robust when
excluding the five SIVmac251 infected animals (data not shown).
On the other hand including these animals notably increased
statistical power by increasing the sample size. Based on viral
loads following achievement of stable set points (that correlated
with absolute peripheral blood CD4+ T cell levels, and clinical
characteristics including hemogram values, weight gain/loss and
blood chemistries, see Table 1) the cohort was stratified into rhe-
sus macaques with low plasma viral load (LVL (n= 24); <105
mean± S.D. viral copies/mL of plasma; slow progression to AIDS)
and rhesus macaques with high plasma viral load (HVL (n= 28);
>105 mean± SD viral copies/mL of plasma; rapid progression
to AIDS). Figure 1 shows box and whiskers plots of viral loads
at set point, indicating that the virus copy numbers are signif-
icantly different (p= 0.0008) and non-overlapping between the
two strata, and Figure 2 underlines the distinctly different survival
times between HVL and LVL. Blood samples from each monkey
were obtained three times prior to SIV infection to derive average
baseline absolute numbers of the various cell lineages. The mon-
keys were bled once per week post infection for 6–8 weeks and
then biweekly for an additional 2 months and monthly thereafter
to monitor plasma viral copy numbers and absolute numbers of
lymphoid cell subsets. Cellular viral loads in aliquots of PBMC
and colorectal biopsy tissue samples were monitored using a tech-
nique standardized in our lab that included negative and positive
controls.
SPECIMEN COLLECTION, MONONUCLEAR CELLS ISOLATION, VIRUS
QUANTITATION
Peripheral blood mononuclear cells (PBMC) were isolated
from heparinized whole blood using standard Ficoll-Hypaque
centrifugation procedure. The cell count and cell viability were
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Table 1 | Overview of the macaque cohort (n=52).
Outcome LVL, n=24 HVL, n=28
Virusa SIVmac239, n=22 SIVmac251, n=2 SIVmac239, n=25 SIVmac251, n=3
Summary statistic Individual data Summary statistic Individual data
Median (range) mm34 mm38 Median (range) mm19 mm25 mm27
Sex 100% male Male Male 100% male Male Male Male
Age at pre-infection (days)
1492 (median) 1680 2061 1555 (median) 1695 1810 1801
658–4549 (min–max) 1024–4570 (min–max)
Intravenously injected viral dose: 1000 TCID50 per animal
CD4+ T cell number in peripheral blood
At pre-infection 1364 (552–2018) 2134 1567 1350(601–2121) 1884 1887 2139
At ≥26 weeks p.i. 918.0 (477–1519) 667 612 150.5 (66–742) 109 73 109
Viral load in peripheral blood
At peak 2.2×106 (4.2×103–32.6×106) 0.3×106 1.1×106 15.0×106 (2.8×106–104.0×106) 10.8×106 21.0×106 6.7×106
At set point 2.4×103 (20–70.2×103) 4.0×103 1.5×103 3.3×106 (0.3×106–36.8×106) 3.0×106 4.0×106 2.0×106
Outcomes of interest
Survival time (in month, censored times indicated by >)
Median >200 month >73 >156 38 month 151 >14 54
First event 146 month 15 month
Last event – 70 month
# Events 1 event 26 events
Viral load in gastro-intestinal tissue
9 (3–27) Missing 6 22 (8–92) 19 46 27
Number of NK cells
At pre-infection 860.5 (668–1229) 831 729 884.0 (612–1242) 933 893 789
≥26 weeks p.i. 639.5 (348–834) 332 673 94.0 (32–143) 87 124 143
%Ki67+ NK cells
At pre-infection 6.7 (4.2–10.3) 5.4 2.7 5.8 (2.9–8.3) 7.3 5.6 7.3
8–12 weeks p.i. 9.3 (4.5–15.6) 9.3 8.4 46.7 (29.6–77.6) 45.6 35.6 19.5
%CD107a-positive NK cells
Pre-infection 18.3 (4.9–37.2) Missing 22.5 23.7 (6.9–42.8) 32.7 13.9 19.3
Acute infection 18.6 (12.3–27.6) Missing 15.4 16.8 (7.2–33.9) 13.2 14.3 6.9
Chronic infection 16.2 (8.1–30.1) Missing 16.9 8.0 (0.1–24.6) 6.9 2.1 0.4
While aminals were comparable at pre-infection, the cohort separated into two distinct subgroups (LVL, HVL) regarding set point viral loads. All other clinical parameters
consistently indicate slow (LVL) or fast (HVL) disease progression.
aVirus strain did not associate with infection outcome (HVL outcome: p=1.00, survival time: p=0.591).
performed using the trypan blue dye technique. The cell concen-
trations were adjusted to 1× 106 cells/mL in complete RPMI1640
media. Aliquots of EDTA plasma were obtained prior to and at
varying intervals following SIV infection and sent on dry ice to
Siemens Laboratories (Siemens, Berkeley, CA, USA) for quan-
titating plasma SIV levels using the branched DNA assay. Data
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FIGURE 1 |Viral loads andT cell numbers. (A) Plasma viral loads at peak and
set point in HVL and LVL animals. Viral loads of HVL and LVL animals differ
significantly at set point (t -test, p=0.0008). (B) Box and whisker plots of CD4+
T cell and CD8+T cell numbers during course of SIV infection in peripheral
blood of HVL and LVL animals. T-tests were performed between the cell
numbers of corresponding time points and were indicated as ****p<0.0001.
obtained are illustrated as plasma VL per milliliter of plasma. For
the quantitation of pro-viral DNA load, aliquots of the unfrac-
tionated PBMCs and cells obtained from the colorectal gut biopsy
tissues collected at various times post infection were used to isolate
total genomic DNA using the Qiagen DNAeasy kit (Qiagen, Valen-
cia, CA, USA). For purposes of brevity, only the data for pro-viral
DNA levels on cells isolated from rectal biopsy samples obtained
during viral load set point (week 8 p.i.) are shown. An aliquot of
the genomic DNA isolated was used to quantitate the amount of
DNA per sample, and the number of viral copies per nanogram
of DNA was determined using our standardized laboratory pro-
tocol for quantitation of SIV gag (22, 23). The SIV1C cell line
that has a single copy of SIV DNA per cell was used as a control
for the pro-viral DNA analysis. The sensitivity of the assay was
one infected cell per million. The quantitation of viral RNA was
performed using RNA extraction, RNAse free primer pairs, and
real-time PCR utilizing SYBR Green for iCycler kit as previously
described (24). The sensitivity of this assay was 10 viral copies/mL.
POLYCHROMATIC FLOW CYTOMETRY AND
FLUOROCHROME-CONJUGATED MONOCLONAL ANTIBODIES
Various fluorochrome-conjugated monoclonal antibodies (mAbs)
were used in appropriate combinations to stain aliquots of the
PBMCs. The mAbs utilized were purchased from BD Biosciences
(San Jose, CA, USA) and included Alexa700-anti-CD3 (clone
SP34-2), PerCP, Pac Blue or V450-conjugated anti-CD4 (clone
L200), FITC or V500-anti-CD8 (clones SK1, RPA-T8), FITC-
anti-CD14 (clone M5E2), PerCP-Cy5.5 or APC-Cy7-anti-CD16
(clone 3G8), APC-Cy7 or PeE-Cy7-anti-CD20 (clones 2H7, L27),
PE-Cy7-anti-CD56 (clone NCAM16.2), APC-anti-CD123 (clone
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FIGURE 2 | Survival times as well as NK cell counts and percentage of
Ki67-positive NK cells during the course of SIV infection in HVL and LVL
animals. (A) Kaplan–Meier survival curve of both strata. (B) Box and whisker
plots of NK cell numbers (upper panel) and % Ki67-positive NK cells (lower
panel). Sampling of cells was before infection (pre) and at indicated weeks
after infection. t -Tests were performed between the cell numbers of
corresponding time points and were indicated as *p<0.05; **p<0.01;
****p<0.0001.
7G3), PerCP-Cy5.5-anti-HLA-DR (clone L243), FITC or PE-
conjugated Ki67 (clone B56), Alexa700 or PE-Cy5-anti-CD107a
(clone H4A3). The PE-anti-NKG2A (clone Z199) was purchased
from Beckman Coulter (Brea, CA, USA) and FITC-anti-human
γδTCR (clone SA6.E9) from Invitrogen. Standard gating strate-
gies were utilized to identify CD3+CD4+αβT cells, CD3+CD8+
αβT cells, CD3+ γδT cells, CD3− CD20+ B cells, CD3− CD8−
NKG2A− CD14+ monocytes, as well as CD3-CD8+ NKG2A+
NK cells and respective subsets based on CD16 and CD56 expres-
sion (25, 26). The cells were incubated with the appropriate
combination of fluorochrome-conjugated antibodies for 30 min
covered with aluminum foil and kept at 4°C. The cells were then
washed twice with FACS buffer and resuspended in FACS buffer
containing 2% paraformaldehyde and kept under aluminum foil
until analyzed using a LSRII flow cytometer (BD Immunocytom-
etry Division, Mountain View, CA, USA). A minimum of 100,000
events were examined per sample and data were analyzed using
FlowJo software (TreeStar, Ashland, OR, USA). An aliquot of the
blood sample was utilized to perform complete blood count and
the values utilized to calculate absolute number of each cell lineage.
NK CELL FUNCTION ANALYSIS
An aliquot of the PBMC sample to be analyzed for NK functional
activity was co-cultured in vitro with HLA class I-devoid K562 or
721.221 cells at an effector/target ratio of 10:1 for 6 h at 37°C in
a humidified 7% CO2 incubator in the presence of Brefeldin-A
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(5 ug/mL, Sigma-Aldrich), Monensin (6 ug/mL, Golgi-Stop, BD
Biosciences) and anti-CD107a (clone LAMP1, BD Biosciences).
Media throughout consisted of RPMI 1640 supplemented with
10% fetal calf serum, 2 mM l-glutamine, 100 units/mL penicillin
and 100 ug/mL streptomycin. Each assay included an aliquot of the
same PBMC cultured alone (negative control) and an aliquot of the
same PBMC incubated with 1.25 ug/mL phorbol-12-myristate 13-
acetate (PMA, Sigma-Aldrich) and 0.25 ug/mL ionomycin (Sigma
Aldrich) as a positive control. Only experiments in which the
negative control gave <10% value and >3-fold increase between
the negative and positive control were considered valid. After
the co-culture, the cells were stained for viability using the Aqua
LIVE/DEAD (Invitrogen) and stained with anti-CD3, CD8 alpha,
NKG2A, CD16 and CD56 antibodies. The cells were washed and
resuspended in the FACS buffer and analyzed using the LSRII flow
cytometer. A minimum of 100,000 events were analyzed and the
frequency of the gated population of CD3−, CD8+, NKG2A+
CD16+ cells that were CD107a+ determined using FlowJo soft-
ware (TreeStar, Ashland, OR, USA). Data obtained in the experi-
mental sample – the negative control was calculated and utilized
to illustrate NK cell functional activity.
NEXT-GENERATION SEQUENCING OFMHC CLASS I AND KIR GENE
TRANSCRIPTS
MHC class I and KIR gene transcripts were analyzed from
PBMC cDNA samples using Roche/454 Titanium chemistry in a
Roche/454 GS Junior sequencer (Roche Applied Science) accord-
ing to previously published methods (18, 27). Amplicon library
preparation, emPCR, bead recovery and sequencing were per-
formed according to the manufacturer’s instructions. Pools of
twelve samples were sequenced on a single PicoTiterPlate. The
emPCR conditions for MHC class I and for KIR amplicon libraries
were performed following the standard protocol instructions
and recommendations for sequencing of long-length amplicon
libraries (≥550 bp), respectively. The ratio of DNA and capture
beads used for emPCR was in the order of 1–2 molecules per
bead.
For each individual, separate library files were generated by
sorting of sequencing reads with identical multiplex identifiers
(MID). Primer sequences were cut off. Only reads with identi-
cal sequences that occurred at least five times were considered in
order to reduce sequencing errors. The filtered reads were aligned
against reference sequences of all known rhesus macaque MHC
class I alleles (IPD MHC database non-human primates http:
//www.ebi.ac.uk/ipd/mhc/nhp/index.html) and rhesus macaque
KIR database (kindly obtained from Dr. Libby Guethlein, Stan-
ford University, USA) using BLAST. Perfectly matching reads were
identified from MHC class I and KIR gene databases. In order
to detect alleles that are not included in these databases, a max-
imum of two mismatches compared to the reference sequences
were allowed. As forward and reverse reads were aligned sepa-
rately, sequences with a maximum of four mismatches, over the
full read length were included in the final preparation of KIR tran-
scription profiles of each rhesus macaque. Since the region of the
sequenced KIR transcripts of about 560 nt (623 nt with primer
regions) is not fully covered by a single read, sufficient counts
(≥5) of matching forward and reverse reads needed to be found.
The overlap between forward and reverse reads covers around one
third (180 nt) of the sequenced part of the KIR gene transcript. We
also tested the KIR profile allowing four or six mismatches (i.e., 8
or 12 in forward+ reverse), but this lead to ambiguous alignments
for some KIR gene transcripts, i.e., matching of single reads to mul-
tiple KIR genes (data not shown). Frequencies of filtered forward
and reverse reads were summed up and the relative contribution
of each KIR transcript was compared to the total number of KIR
transcripts identified in each individual. The MHC class I and KIR
gene transcript sequencing data of the entire 52 rhesus macaques
are shown in Tables S1 and S2 in Supplementary Material.
STATISTICAL ANALYSES
The various statistical software programs used included SAS, R,
and GraphPad Prism 6.
Time-course of NK cell numbers from 8–12 weeks p.i. to 26
to >26 weeks p.i. was analyzed by longitudinal linear regression,
testing statistical interaction between covariates time and group
(HVL, LVL) (see Figure 2). Difference of means of % Ki67+ NK
cells at 8–12 weeks p.i. between HVL and LVL animals was exam-
ined by t-test; and the lytic function of NK cells was analyzed in
HVL and LVL by repeated measures ANOVA (Figure 3, testing
change of mean%CD107a-positive NK cells over time, i.e., from
pre- to acute and chronic infection).
Target HVL outcome was analyzed by logistic regression, sur-
vival times by Cox regression, and NK cell number and corre-
sponding functional data as well as viral loads in gut tissue by linear
regression models, testing KIR main effects (Table 3, multiple or
single KIR covariates as indicated) and KIR–MHC class I epistasis
(see Table 4 and Figures 5 and 6; statistical interaction models con-
tained a KIR and a MHC-I covariate, respectively). Furthermore,
for the main target HVL outcome, we compared a multiple model
(multi-KIR) with univariate analyses (single-KIR) (see Table 3,
FIGURE 3 | Cytotoxic capacity of NK cells during different phases of
SIV infection in HVL and LVL animals. Degranulation after stimulation
with MHC class I-deficient cells was determined as % CD107a-positive NK
cells. Acute and chronic phases represent time points 2–4 weeks and
>16 weeks after infection.
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first columns). In contrast to single-KIR analyses, the multi-KIR
model estimates mutually adjusted KIR main effects and accounts
for correlations between KIR genes (a priori excluded were KIR
genes that had small strata size or strong correlations with other
KIR genes). In addition, the frequency of KIR transcript sequence
reads at pre- and acute-infection (where NK cell numbers were
high and comparable across HVL and LVL) was jointly analyzed
in KIR-positive animals as longitudinal metric target by longitudi-
nal rank-sum test (28) for association with HVL outcome (Table 3,
last column). Rank-sum testing ensured test validity given that KIR
transcript frequencies had skewed distributions. The rank-sum
test resembles a heteroscedastic 1-way repeated measures ANOVA
with factor HVL outcome on the longitudinal rank-order data of
observed KIR transcript frequencies. Longitudinal analyses incor-
porated all animals that had any trait data (number of animals
is indicated in Table 3; no omission of animals with incomplete
follow-up and no imputation of missing values). We used SAS
procedure mixed for longitudinal linear regression on% CD107a-
positive NK cells and R package nparLD for longitudinal rank-sum
testing of relative KIR transcript amounts (Table 3).
Association between MHC class I alleles and HVL outcome was
tested by Fisher’s exact tests (see Table S3 in Supplementary Mater-
ial). Finally, the probability to obtain K p values≤ 0.05 for a family
of M association tests with HVL outcome was estimated under the
null hypothesis of no associations, based on 10,000 data replicates
with randomly permuted HVL/LVL group assignment.
RESULTS
NK CELL NUMBERS, PROLIFERATION, AND ACTIVITY DURING SIV
INFECTION
The cohort of rhesus macaques (n= 52) was experimentally
infected with SIV (SIVmac) and subsequently stratified into ani-
mals with “low viral load” (LVL) and “high viral load” (HVL)
based on viral load at set point (Figure 1A). Disease progressed
much faster in HVL compared to LVL as indicated by absolute
levels of blood CD4+ T cell counts and other clinical parameters
(see Table 1 and Materials and Methods for details). The marked
differences between HVL and LVL animals are further exemplified
by a Kaplan–Meier survival curve (hazard ratio 80.7, p= 0.00002;
Figure 2A). Table 1 shows a summary of the cohort and relevant
data that are also displayed in Figures 1–3.
The disease course in HVL and LVL animals displays the typical
marked (p< 0.0001) decline of CD4+ T cell counts in both strata
(Figure 1B). Whereas the numbers of CD8+ T cells were rather
similar (Figure 1B),we observed differences in blood NK cell num-
bers in LVL and HVL animals (Figure 2B). An increase of NK
cell numbers during the acute phase of SIV infection (2–6 weeks
p.i.) was followed by a steady decline in both strata. However, in
contrast to LVL animals, HVL animals displayed a more marked
decline in the number of NK cells during the chronic phase of
infection by−30.6 per week (95% CI [−36.3,−24.9]; p< 0.0001).
At 26 weeks p.i. and beyond, the mean absolute number of NK cells
per µL blood in the HVL stratum was lower by −547.2 (95% CI
[−608.6,−485.9]; p< 0.0001) compared to LVL animals. The pro-
liferation of NK cells (% Ki67+) peaked during the acute phase
of infection (2 weeks p.i.) in both strata (Figure 2B). Interestingly,
the percentage of Ki67+NK cells rapidly declined in LVL animals
and reached pre-infection levels at 8–12 weeks p.i. with a mean
value of 9.7% (95% CI [8.7, 10.8]), whereas in contrast a signif-
icantly higher amount of proliferating NK cells was observed in
HVL animals as long as 8–12 weeks p.i. (t -test, p< 0.0001) with
a mean value of 46.4% (95% CI [42.3, 50.4]) Ki67+ NK cells
that was sustained significantly (p< 0.0001) at high levels dur-
ing the chronic phase of infection. Thus, blood NK cells in HVL
animals had higher proliferation activity than in LVL animals par-
ticularly at time points 4–12 weeks p.i., a time interval when NK
cell numbers of both strata are still comparable.
Next we determined the capacity of NK cells from LVL and
HVL animals to lyse MHC class I-deficient cells in a degranula-
tion assay using samples obtained at different time points post
infection. The percentage of CD107a+NK cells during transition
from pre-infection to acute and chronic phases declined in HVL
animals (repeated measures ANOVA, p< 0.0001), but remained
stable in LVL animals (p= 0.3086) (Figure 3).
Collectively, these data demonstrate that NK cells from ani-
mals with fast progression to AIDS and shorter survival times
had sustained proliferation after SIV infection, but lost their lytic
capability and constantly decreased in number following peak viral
load.
KIR HETEROGENEITY IN THE RHESUS MACAQUE COHORT
As KIR proteins essentially regulate the activity of NK cells, we
determined the KIR gene transcripts by next-generation sequenc-
ing (Table S1 in Supplementary Material). Baseline values obtained
pre-infection, showed similar NK cell numbers that ensured com-
parable transcript detection sensitivity across all animals. We
found a similar gene diversity and frequency distribution of
transcript-positive animals in our cohort as previously published
by others (17, 18) for Indian rhesus macaques (Figure 4A). The
most frequently transcribed KIR gene in our cohort was KIR3DL01
(92%, n= 48), KIR genes particularly rarely transcribed were
KIR3DL04 (2%, n= 1), KIR3DL06 (4%, n= 2), KIR3DS01 (12%,
n= 6), KIR3DS04 (10%, n= 5), and KIR3DS06 (13%, n= 7).
Similar to the cohort analyzed by Moreland and co-workers (18),
we detected no transcripts of the KIR3DS07 gene in our cohort.
Thus, the KIR gene diversity in our cohort is comparable to other
cohorts.
ASSOCIATION OF KIR ANDMHC CLASS I POLYMORPHISMSWITH
PROGRESSION TO AIDS
We initially tested whether the presence of individual KIR genes is
correlated, for example due to close genetic linkage, which has
hitherto not been determined for rhesus macaque KIR genes.
Of particular interest for subsequent genetic association analy-
ses with SIV infection outcome are strong correlations as well as
distinctly different correlations in HVL compared to LVL. The
latter may occur in the vicinity of functionally relevant genes
when specific haplotypes associate with HVL outcome. As can
be seen in Table 2, correlation between KIR3DL05–KIR3DS05–
KIR3DL10 and KIR3DSW08–KIR3DLW03–KIR3DSW09 strongly
suggests that these are neighboring genes (in the given order).
Stronger correlation in HVL compared to LVL animals may indi-
cate some functional relevance of these gene sets to infection
outcome and differences in KIR haplotypes.
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FIGURE 4 | KIR genes in SIV infected rhesus macaques with slow
(LVL, n=24) and rapid (HVL, n=28) progression to AIDS. (A,B)
Relative percentage of animals displaying the KIR transcript (bar
height) with 95% confidence limits (error bars). The number n of
animals transcribing the respective KIR gene is given below the bars.
(A) Complete cohort of n= 52 rhesus macaques. Boxes indicate
correlated KIR genes (KIR3DL10–KIR3DS05–KIR3DL05 ;
KIR3DSW08–KIR3DLW03–KIR3DSW09; seeTable 2). (B) Cohort
stratified into HVL (n=28) and LVL (n=24) animals. (C) KIR transcript
frequencies of animals transcribing the KIR3DL02 or the KIR3DL05
gene before (pre) and during different time points after infection
(acute, chronic).
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Table 2 | Correlation of KIR transcript presence at pre-infection.
Whole cohort (n=52) HVL animals (n=28) LVL animals (n=24)
KIR3DS05 KIR3DLW03 KIR3DS05 KIR3DLW03 KIR3DS05 KIR3DLW03
KIR3DL10a 0.74 (p=5.2×10−10) 0.70 (p=4.3×10−5) 0.75 (p=2.9×10−5)
KIR3DL05a 0.42 (p=0.0023) 0.84 (p=3.9×10−8) −0.04 (p=0.84)
KIR3DSW08b 0.56 (p=1.6×10−5) 0.74 (p=9.6×10−6) 0.45 (p=0.027)
KIR3DSW09b 0.35 (p=0.012) 0.61 (p=8.0×10−4) 0.12 (p=0.57)
Displayed correlations (Pearson estimate, p value) were strong enough to have p≤10−3 in HVL or LVL (significances in bold, Bonferroni: p≤0.05/240=2.08×10−4
for testing pair wise correlations of 16 KIRs in HVL and LVL). KIR3DL04 (2%), KIR3DL06 (4%), KIR3DL01 (92%) were not tested.
aKIR3DL10 tended to correlate with KIR3DL05 in the whole cohort (r=0.35, p=0.013) and in HVL (r=0.55, p=0.003) but not in LVL (r=0.10, p=0.65).
bKIR3DSW08, KIR3DSW09 were uncorrelated in the whole cohort (r=−0.01, p=0.92) with opposing but non-significant tendencies in HVL (r=0.18, p=0.36) and
LVL (r=−0.19, p=0.39).
For KIR association analyses (Table 3) we converted levels of
KIR transcript at pre-infection into binary variables that were sub-
sequently used as covariate(s). Target traits for association analyses
included HVL outcome (logistic regression), survival time (Cox
regression), NK cell number and functional data (linear regres-
sions). KIR effect estimates were mutually adjusted in a single
multi-KIR model of HVL outcome, which was the main target
(Table 3, first column, significances p≤ 0.05 in bold; excluded
were KIRs with small strata size, and KIR3DS05 and KIR3DLW03
because of strong correlations with neighboring KIR genes as
shown in Table 2). All other association analyses in Table 3
employed single-KIR models. Furthermore, the frequency of KIR
transcript sequence reads at pre- and acute-infection (where NK
cell numbers were high and comparable across HVL and LVL) was
jointly analyzed in KIR-positive animals as a longitudinal metric
target for association with HVL outcome (Table 3, last column).
The presence of transcripts for KIR3DL02 and KIR3DSW08
was associated significantly with LVL outcome (see Table 3: sig-
nificant odds ratios =1 and Figure 4B). The observable weaker
power of the KIR3DSW08 gene is attributed to its low frequency.
Additionally, a trend for the even rarer gene KIR3DS01 to be
protective was identified by the single-KIR model (Table 3, OR
0.15, p= 0.0504). KIR3DS02 was detected as a risk gene for HVL
outcome, especially when KIR correlations were accounted for
in the multi-KIR model (Table 3; OR 46.5, p= 0.008). Further-
more, KIR3DL10 associated with HVL outcome (Table 3, OR
3.75, p= 0.025) in single-KIR analysis; with a similar trend for
correlated gene KIR3DS05 (Table 3; OR 2.83, p= 0.068), whereas
the multi-KIR model implicated presence of KIR3DL05 to asso-
ciate with LVL outcome (Table 3, OR 0.09, p= 0.037). This
difference arises from the intricate correlation structure between
KIR3DL05–KIR3DS05–KIR3DL10 described above. The associa-
tion of KIR3DS05 and KIR3DL10 with HVL outcome was under-
scored by subsequent epistasis analyses with MHC class I alleles
(see below).
Table 3 further illustrates that the association of KIR genes with
HVL outcome is mirrored in clinical (survival time) and func-
tional (decline of blood NK cell numbers, sustained blood NK cell
proliferation, and loss of blood NK cell lytic function) parame-
ters. Indeed, transcription of the protective KIR genes 3DL02 and
3DSW08 is in both cases significantly associated with (1) longer
survival time (3DL02: HR 0.24, p= 0.005; 3DSW08: HR 0.29,
p= 0.020), (2) higher numbers of blood NK cells (3DL02:+ 220.7,
p= 0.006; 3DSW08:+ 222.8, p= 0.014), and (3) lower numbers
of proliferating NK cells (3DL02: −15.7%, p= 0.005; 3DSW08:
−13.2%, p= 0.025). Expression of KIR3DL02 is further associ-
ated with better preservation of lytic capability (+6.7% CD107a
positive, p= 0.033) and higher transcript frequencies in LVL ani-
mals compared to HVL animals (Table 3; Figure 4C, p= 0.033).
Expression of the putatively protective KIR3DS01 gene is associ-
ated with longer survival time (HR 0.20, p= 0.041) and higher
NK cell numbers (+ 243.9, p= 0.042) and by trend also with
less NK cell proliferation (−15.5%, p= 0.076) (Table 3), further
underscoring the finding that KIR3DS01 might be a protective
KIR gene. Along the same line, transcription of the risk genes
KIR3DL10 and KIR3DS02 is in both cases associated with shorter
survival times (KIR3S02: HR 2.96, p= 0.043: KIR3DL10: bor-
derline significance HR 1.96, p= 0.088), and with a decrease in
NK cell numbers (KIR3DL10:−180.5, p= 0.017; KIR3DS02: bor-
derline significance−169.0, p= 0.065). KIR3DL10 is significantly
associated with reduced lytic activity of NK cells (−6.4% CD107a-
positive cells, p= 0.035) and both KIR3DL10 and KIR3DS02 show
a trend for sustained proliferating NK cells at 8–12 weeks p.i. (both
p= 0.056) (Table 3). Of note, all single-KIR effect estimates in
Table 3 for KIR3DS02 are remarkably similar to those of cor-
related KIR genes 3DL10, 3DS05 across all analyses. Moreover,
the most frequent KIR gene KIR3DL05 in the correlated triplet
(3DL05–3DS05–3DL10) and the highly frequent KIR3DS02 tend
to correlate (whole cohort: r = 0.41, p= 0.0031, HVL stratum:
r = 0.54, p= 0.0034, LVL stratum: r = 0.30, p= 0.156, not signifi-
cant after Bonferroni correction). Notably, KIR3DL05 is associated
with higher transcript frequencies in HVL animals compared to
LVL animals (Table 3; Figure 4C, p= 0.022).
Furthermore, we determined the transcribed MHC class I alle-
les and identified 68 distinct Mamu-A and Mamu-B transcripts in
the entire cohort of 52 rhesus macaques (see Table S2 for individ-
ual data and Table S3 for MHC class I gene/allele frequencies in
Supplementary Material), with an average of 10 distinct transcripts
per individual. We frequently observed coincidence of particular
MHC class I transcripts (see Table S4 in Supplementary Material)
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Table 3 | KIR association with HVL outcome, survival and NK cell function.
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Binary covariate (s) KIR transcript presence at pre-infection HVL outcome
Multi-KIR Single-KIR Single-KIR Single-KIR Single-KIR Single-KIR
At≥26
weeks p.i.
At 8–12
weeks p.i.
Longitudinal
time-course
Longitudinal
level
KIR OR (P ) OR (P ) HR (P ) ∆ (P ) ∆ (P ) ∆ (P ) Rank-sum
test (P )
1D 0.60 (0.656) 1.21 (0.735) 1.12 (0.777) −0.69 (0.993) 0.4 (0.947) −1.0 (0.755) (0.464)
3DL01 – – – – – – – – – – – – (0.358)
3DL02 0.01 (0.0007) 0.13 (0.002) 0.24 (0.005) 220.7 (0.006) −15.7 (0.005) 6.7 (0.033) (0.033)
3DL04 – – – – – – – – – – – – –
3DL05g 0.09 (0.037) 1.21 (0.735) 1.29 (0.536) −48.7 (0.546) 1.6 (0.773) 1.1 (0.850) (0.022)
3DS05g – – 2.83 (0.068) 1.84 (0.127) −118.8 (0.128) 7.7 (0.174) −4.7 (0.172) (0.228)
3DL10g 0.98 (0.989) 3.75 (0.025) 1.96 (0.088) −180.5 (0.017) 10.9 (0.056) −6.4 (0.035) (0.521)
3DL06 – – – – – – – – – – – – –
3DL07 5.26 (0.166) 1.43 (0.562) 1.46 (0.401) −27.6 (0.750) 5.8 (0.330) 1.5 (0.831) (0.291)
3DL08 17.24 (0.211) 1.06 (0.921) 1.11 (0.798) 15.9 (0.841) 0.5 (0.933) −1.9 (0.456) (0.150)
3DL11 0.47 (0.452) 0.41 (0.137) 0.47 (0.083) 116.4 (0.155) −8.2 (0.165) 3.3 (0.410) (0.688)
3DS01 – – 0.15 (0.0504) 0.20 (0.041) 243.9 (0.042) −15.5 (0.076) 5.1 (0.367) (–)f
3DS02 46.50 (0.008) 2.88 (0.118) 2.96 (0.043) −169.0 (0.065) 11.6 (0.056) −3.8 (0.379) (0.277)
3DS03 0.06 (0.238) 1.26 (0.711) 1.08 (0.861) −53.1 (0.548) 3.3 (0.610) 1.3 (0.695) (0.669)
3DS04 – – 0.56 (0.541) 0.59 (0.448) 109.1 (0.410) 3.2 (0.741) 3.2 (0.638) –
3DS06 – – 2.50 (0.283) 2.07 (0.182) −140.9 (0.216) 3.5 (0.656) −3.4 (0.514) –
3DSW08g 0.10 (0.038) 0.21 (0.025) 0.29 (0.020) 222.8 (0.014) −13.2 (0.025) 1.6 (0.640) (–)f
3DLW03g – – 0.55 (0.371) 0.62 (0.322) 90.3 (0.330) −9.2 (0.127) −1.8 (0.268) (0.772)
3DSW09g 0.02 (0.084) 0.66 (0.574) 0.74 (0.570) 120.9 (0.240) −8.0 (0.210) −1.8 (0.353) (0.732)
P values ≤0.05 in bold (significance in the multi-KIR model). Rare KIR3DL04, KIR3DL06 (n≤2 with this KIR) were not analyzed. The most frequent KIR3DL01 (n=4
without this KIR) was only analyzed for frequency of KIR transcript sequence reads.
aLogistic regression for target HVL outcome, with a single KIR or multiple KIR covariate(s): odds ratio (OR, <1 for protective KIR) and p value (P) (likelihood ratio test,
χ2 statistic). ORs in the multi-KIR model are mutually adjusted within a single model [for KIRs with strata sizes ≥9 animals; excluding 3DS05, 3DLW03 due to strong
correlations (seeTable 2)].
bCox proportional hazards model with a single KIR covariate: hazard ratio (HR, <1 for protective KIR) and p value (P) (likelihood ratio test, χ2 statistic).
cLinear regression for target number of NK cells, with a single KIR covariate: P value (P) (t statistic) and KIR effect ∆ (difference of trait means; ∆>0 indicates a
protective KIR that associates with higher NK cell numbers at ≥26 weeks p.i.).
dLinear regression for target %Ki67+ NK cells, with a single KIR covariate: P value (P) (t statistic) and KIR-effect ∆ (difference of trait means; ∆<0 indicates a
protective KIR that associates with moderated NK cell proliferation at 8–12 weeks p.i.).
eLongitudinal target %CD107a-positive NK cells at pre-, acute, and chronic infection, analyzed by 1-way repeated measures ANOVA with factor KIR (n=47 animals
with data): P value (P) (ANOVA-F statistic for KIR× time interaction) and effect ∆ in KIR carriers (difference between chronic and pre-infection trait means, compared
to animals without KIR transcript). Note that in the cohort%CD107a-positive cells reduce over time (p<0.0001) by −9.6%-points between pre- and chronic infection
(see Figure 2). Thus, a KIR effect of 0<∆<9.6 implies moderated loss-of-function (protective KIR), ∆<0 enhanced loss-of-function (deleterious KIR).
fLongitudinal target KIR transcript frequency at pre- and acute infection (where NK cell numbers are still high), analyzed by longitudinal rank-sum test (heteroscedastic
1-way repeated measures ANOVA with factor HVL outcome on longitudinal rank-order data of the target). Analyses (a–e) above comprised the whole cohort; this
analysis (f) only KIR positive animals [see Figure 4B for subsample sizes; rare KIR’s, e.g., KIR3DS01 (5 LVL, 1 HVL) and KIR3DSW08 (9 LVL, 3 HVL) were not analyzed].
P values (P) for association of KIR transcript frequency with HVL outcome; KIR3DL02 and KIR3DL05 are illustrated in Figure 4C.
gKIR3DL10–KIR3DS05–KIR3DL05 and KIR3DSW08–KIR3DLW03–KIR3DSW09 are correlated (seeTable 2).The particularly strongly correlated middle KIR was excluded
from the multi-KIR model.
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Table 4 | KIR3DS05, KIR3DL10 epistasis with MHC class I alleles on HVL risk.
KIR3DS05 KIR3DL10
MHC class I KIR3DS05 Epistasis Pa MHC class I KIR3DL10 Epistasis Pa
MHC
class I
ORMHC
(p value)
ORKIR
(p value)
ORMHCxKIR
(p value)
ORMHC
(p value)
ORKIR
(p value)
ORMHCxKIR
(p value)
A1*001 1.50 (p=0.622) 21.60 (p=0.009) 0.035 (p=0.020) 0.041 1.40 (p=0.654) 21.60 (p=0.009) 0.036 (p=0.024) 0.041
A1*004 11.00 (p=0.015) 7.33 (p=0.034) 0.20 (p=0.224) 3.64 (p=0.101) 3.25 (p=0.167) 1.10 (p=0.942)
B*012 0.50 (p=0.471) 1.25 (p=0.755) 10.00 (p=0.087) 0.40 (p=0.320) 1.20 (p=0.811) 25.00 (p=0.036)
B*046 2.67 (p=0.283) 4.40 (p=0.044) 0.26 (p=0.272) 1.30 (p=0.745) 3.66 (p=0.084) 1.03 (p=0.984)
B*057 6.42 (p=0.040) 6.60 (p=0.028) 0.17 (p=0.153) 2.60 (p=0.221) 4.33 (p=0.089) 0.58 (p=0.659)
B*072 10.29 (p=0.047) 20.01 (p=0.014) 0.054 (p=0.043) 3.00 (p=0.179) 8.00 (p=0.029) 0.29 (p=0.330)
Displayed are all model term estimates (main effects and epistasis: odds ratio’s OR (p values), p≤0.05 in bold) for twelve models of KIR–MHC class I polymorphism
pairings. The two correlated KIR risk genes KIR3DS05 and KIR3DL10 were coded for transcript presence at pre-infection. The MHC class I alleles were coded for
transcript presence, did not correlate significantly, and were frequent with sufficient strata sizes.The simultaneous risk estimates ORMHC, ORKIR, and ORMHCxKIR quantify
HVL risk of MHC-I in KIR-negative animals (ORMHC), HVL risk of KIR in MHC-I-negative animals (ORKIR) and epistatic effects for coincident presence of KIR and MHC-I
(ORMHCxKIR). Animals with coincident MHC-I and KIR presence have the HVL risk ORMHC·ORKIR·ORMHCxKIR compared to animals with coincident MHC-I and KIR absence.
aProbability that – under the null-hypothesis of no epistasis and no genetic associations – two or more p≤0.05 for six epistasis tests of MHC class I alleles with a
KIR gene. This probability was estimated based on 10,000 permutations of the HVL/LVL group assignment.
that were previously found to co-occur on distinct MHC class I
haplotypes (29, 30). It should be noted that rhesus macaque MHC
class I haplotypes display extensive CNV of Mamu-B genes (29,
31–33). We found Mamu-A1*004 transcripts more frequently in
the HVL than in the LVL stratum (OR 3.7, p= 0.029) (see Table S3
in Supplementary Material), and in accord with previous studies
also Mamu-A1*001 (OR 0.4, p= 0.163) and the rare allele Mamu-
B*008 (OR 0.0, p= 0.208) more frequently in the LVL than in the
HVL stratum (not reaching significance for the latter two).
ANALYSES OF COMBINATIONS OF KIR ANDMHC CLASS I
POLYMORPHISMS AND PROGRESSION TO AIDS
KIR3DL1/3DS1 in combination with HLA-Bw4-80I allotypes (in
particular HLA-B*57) are associated with slow progression to
AIDS in human HIV infection (8, 9, 11, 34). Knowledge of the
contribution of similar combinations of KIR and MHC class I
alleles is currently not available in the model of SIVmac infection
of rhesus macaques.
Sufficient strata sizes for epistasis analyses of KIR and MHC
class I transcript presence were available for MHC class I alleles
with cohort frequencies between 34.6 and 46.2% when combined
with KIR genes with about 50% sample frequency. Of these KIR
genes, the correlated putative risk genes KIR3DS05, KIR3DL10
were the most interesting. Analyses of epistasis on HVL out-
come (Table 4) consistently revealed higher power for KIR3DS05
as well as deleterious effects of KIR3DS05 and Mamu-A1*004.
Epistasis test p values in Table 4 were not particularly signif-
icant. However, observing two (out of six) p≤ 0.05 only had
a probability p= 0.041 under the null-hypothesis of no epis-
tasis and no genetic associations. Moreover, model estimates
of KIR3DS05 and KIR3DL10 with Mamu-A1*001 were remark-
ably consistent. They indicate that the presence of KIR3DS05 or
KIR3DL10 transcripts in Mamu-A1*001-negative animals asso-
ciated with a 21.6-times higher HVL risk (p= 0.009). However,
presence of Mamu-A1*001 transcripts annulled this detrimental
effect of KIR3DS05, KIR3DL10 (epistasis p≤ 0.024; yielding an
odds ratio of 1.1 for combined presence of Mamu-A1*001 with
KIR3DS05 or KIR3DL10).
Whereas Mamu-B*012 per se did not influence disease out-
come according to our analysis (Table 4), there was a tendency
of a higher HVL risk in animals with coincident presence of
Mamu-B*012 with KIR3DS05 or KIR3DL10 transcripts (poten-
tial epistasis; note also the consistency of model estimates of
Mamu-B*012 with KIR3DS05 and KIR3DL10). Furthermore, it is
of interest to note that Mamu-A1*004, Mamu-B*012, and Mamu-
B*057 co-occur on MHC class I haplotypes that were previously
reported for other rhesus macaques of Indian origin with rapid or
intermediate SIV-disease progression (30).
While ORs had considerable estimation uncertainty (as is com-
mon in epistasis analyses), the epistasis of Mamu-A1*001 and
Mamu-B*012 with KIR3DS05, and KIR3DL10 on HVL outcome
was also observed for viral copy numbers in GIT (Figure 5), and for
survival time (Figure 6). In Mamu-A1*001-negative animals, viral
copy numbers in GIT were particularly high in animals expressing
KIR3DS05 and KIR3DL10: 23.9 (p= 0.0081) or 21.8 (p= 0.017)
more copies on average, respectively (Figure 5A). A similar trend
can be seen in animals expressing the correlated KIR3DL05 gene
(17.2, p= 0.076). However, presence of Mamu-A1*001 transcripts
is associated with an effect that is contrary to the KIR3DL05,
KIR3DS05, and KIR3DL10 main effects. In animals expressing
KIR3DS05, the presence of Mamu-A1*001 transcripts was associ-
ated with decreased viral copies by −31.6 on average (p= 0.015).
Similar trends were seen in animals expressing KIR3DL10 or
KIR3DL05, where the presence of Mamu-A1*001 transcripts coin-
cided with decreased viral copy numbers by −17.3 (p= 0.19)
or −20.6 (p= 0.13) on average (Figure 5A). Coincident pres-
ence of Mamu-B*012 with KIR3DL05, KIR3DS05 or KIR3DL10
transcripts resulted in 32.8 (p= 0.0173), 34.7 (p= 0.0091) or
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FIGURE 5 | Epistasis of the correlated KIR3DL05–KIR3DS05–KIR3DL10
genes with Mamu-A1*001 and Mamu-B*012 on viral copy numbers in
GIT. The boxplots of viral copy numbers stratify for presence (+) and absence
(−) of Mamu-A1*001 or Mamu-B012 and the respective KIR (left panels:
KIR3DL05, middle panels: KIR3DS05, right panels: KIR3DL10) transcripts.
Sample sizes n are displayed at the bottom of the graphs. (A) Illustrated are
the KIR main effects (directly observed in Mamu-A1*001-negative animals)
and the epistatic effects of Mamu-A1*001 in KIR3DL05-, KIR3DS05-, or
KIR3DL10-positive animals. (B)The epistasis model with Mamu-B*012
revealed consistent epistatic effects but no KIR main effects, suggesting that
the KIR main effects (seeTable 3 and this figure, partA) may be marginal
effects from an epistasis with Mamu-B*012.
35.1 (p= 0.0074) more viral copies on average, respectively
(Figure 5B), confirming the suspected epistasis. Interestingly, no
KIR main effects were seen in the epistasis models with Mamu-
B*012 (Figure 5B). This suggests that the KIR3DS05, KIR3DL10
main effects in the single-KIR analyses in Table 3 as well as
in Figure 5A may be marginal effects from an epistasis with
Mamu-B*012.
Figure 6 illustrates the fact that the presence of KIR3DL10
transcripts when combined with lack of Mamu-A1*001 or with
presence of Mamu-B*012 transcripts also led to shorter survival
times, confirming the epistasis. Highly similar results were
obtained for the correlated but the more rare KIR3DS05 gene and
for KIR3DL05 (not shown), albeit with weaker power.
DISCUSSION
Our understanding of the biology of NK cells continues to evolve.
Besides its killer function,data supporting the ability of cells within
this lineage to become educated, acquire memory and participate
in a number of immune regulatory function are accumulating
(35–39). Consequently, the role of NK cells in HIV-1 infection
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FIGURE 6 | Epistasis of Mamu-A1*001 and Mamu-B*012 with
KIR3DL10 on survival time. The data for KIR3DS05 are highly similar and
are, therefore, not shown. Epistasis effect estimates on survival were
consistent for KIR3DL10 (see figure) and KIR3DS05
(KIR3DS05 ×Mamu-A1*001: detrimental KIR effect HR 4.32, p=0.0102,
and epistasis HR 0.20, p=0.0532; KIR3DS05 ×Mamu-B*012: epistasis HR
6.35, p=0.0535).The more frequent KIR3DL10 had higher statistical power.
and its corresponding non-human primate model has attracted
much attention in AIDS research (20, 34, 40, 41). Particular
attention in human HIV-1 infection has been paid to genetic fac-
tors that modulate NK-cell function and susceptibility to disease.
Key determinants of NK-cell activation are the highly polymor-
phic KIR receptors and their MHC class I ligands. While human
KIR3DL1/S1 allotypes in combination with HLA-B allotypes car-
rying the serological Bw4 epitope with an isoleucine residue at
position 80 (HLA-Bw4-80I) were identified as protective, such
combinations were hitherto not known in the rhesus macaque
SIV infection model.
Based on viral load at set point that correlated well with clini-
cal course (time to the development of AIDS) and absolute levels
of peripheral blood CD4+ T cells, we grouped rhesus macaques
experimentally infected with SIVmac into “HVL” and “LVL” strata.
In contrast to LVL animals that had a relatively benign disease
course, we found a progressive loss of peripheral blood NK-cell
numbers after peak viraemia in animals rapidly succumbing to
SIV-mediated disease (HVL). Further distinguishing HVL from
LVL animals is a considerably higher percentage of proliferat-
ing (% Ki67+) peripheral blood NK cells in HVL animals as
long as 8–12 weeks p.i. (corresponding roughly with viral set
point) when NK cell numbers were still high and comparable in
both strata. This “proliferating” phenotype of NK cells in HVL
animals (Figure 2B), however, is not associated with increased
cytotoxic activity as evidenced by decreased CD107a-positive NK
cells (Figure 3), indicating dysfunction of NK cells. Dysfunctional
NK cells have been reported in HIV-1-infected individuals (42–
44) and in SIV-infected rhesus macaques (45). Recent studies
highlighted an important role of NK cells in the regulation of
CD4+ and CD8+ T cell subsets in various viral infections (38,
46, 47). For example depending on the viral titer, LCVM infec-
tion is lethal to mice, but results in viral clearance if NK cells are
depleted (38) or NK-cell deficient mice are used (46). The regu-
latory role of NK cells is exerted via killing of CD4+ or CD8+
T cells, leading to failure of CD8+ T-cell support and CD8+
T-cell responses. Consequently, depletion of NK cells improves
CD8+ T-cell killing of virus-infected cells, enhances T-cell immu-
nity and reduces immune pathology. Depending on the virus, such
killing of T cells is perforin dependent or is achieved indirectly via
cytokines released by NK cells. The reduced degranulation of NK
cells in the HVL animals leads us to hypothesize that the T-cell
response is affected in the SIV-infected HVL animals via NK cells’
cytokine secretion. Indeed, it has been proposed that cytotoxic
CD16+ NK cells have only a limited role in the control of SIV
(48). According to our data, this regulation obviously preferen-
tially affects the CD4+ as compared with the CD8+ T-cell subset
(Figure 1) and might be particularly effective in HVL animals 4–
12 weeks p.i., a time point when NK cell numbers are still high
and about 50% of these NK cells are proliferating (activated) in
contrast to only 10–20% NK cells in the LVL cohort.
Control of lentiviruses might be influenced by NK cells at the
local viral entry site with an important contribution by a NK
cell subset that is uniquely present in such mucosal tissues (49).
Indeed, rhesus macaques infected intra-rectally or intra-vaginally
with SIVmac251 showed some functional differences of mucosal
and blood NK cells, including a higher lytic capacity (% CD107a
expression) of mucosal NK cells (50). However, whether differ-
ences in KIR expression are evident and responsible for these
phenomena is currently not known.
We hypothesized that the observed functional differences of
NK cells and the different disease outcomes are due to KIR and
MHC class I polymorphisms. However, comprehensive molecu-
lar typing of KIR and MHC class I polymorphisms at the DNA
level is extremely complicated in rhesus macaques due to large
expansions of both gene families and extensive copy-number
variations as well as an absence of detailed genomic informa-
tion of haplotypes (only single KIR and MHC class I haplotypes
are completely sequenced). Therefore, we used published next-
generation sequencing approaches to determine transcripts of
both rhesus macaque gene families (18, 27) and analyzed the risk
of HVL outcome. Our study identified the inhibitory KIR3DL02
and the activating KIR3DSW08 (and most probably KIR3DS01)
genes as protective factors in the rhesus macaque SIV infection
model (Table 3; Figure 4). The activating KIR3DS02 gene was
detected as a risk gene, but only when KIR correlations were
accounted for (multi-KIR model, Table 3). Of note, KIR3DS02
had a certain correlation with the cluster KIR3DL05–KIR3DS05–
KIR3DL10, in particular with KIR3DL05 (whole cohort: r = 0.41,
p= 0.0031; HVL stratum: r = 0.54, p= 0.0034; LVL stratum:
r = 0.30, p= 0.156; non-significant after Bonferroni correction),
and was in all single KIR analysis consistent with this KIR gene
cluster (Table 3). While no specific ligand has so far been reported
for KIR3DL02, a suggested ligand for KIR3DSW08 is Mamu-
A3*13 (51). In accord with this, the Mamu-A3*13 allele (formerly
designated Mamu-A*13) was reported to be associated with longer
survival times of SIV-infected rhesus macaques (52) and is present
on MHC haplotypes that were associated with slow, but also
intermediate and rapid SIV disease progression (30). Unfortu-
nately, frequencies of KIR3DL02 and KIR3DSW08 in the cohort
(see Figure 4B, Table S1 in Supplementary Material) were not
high enough to include both in the epistasis analyses. In addi-
tion, we had to exclude rare KIR genes (KIR3DL04, KIR3DL06 ;
n≤ 2,≤ 3.8%) or KIR genes with high frequency (KIR3DL01;
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n= 48, 92.3%). Nevertheless, as about half of the animals (46%)
belong to the LVL group, rare or very frequent genes are not
expected to be responsible for the observed differences between
LVL and HVL animals. Of note, the relative amounts of KIR tran-
scripts were higher in LVL for the KIR3DL02 gene and higher in
HVL animals for the KIR3DL05 gene, respectively (Figure 4C),
supporting the aforementioned findings. Although we cannot
exclude that these KIR genes show increased transcription, a more
likely explanation for this observation appears to be a higher
percentage of cells expressing these KIR genes, probably due to
clonal expansions (T cells) or education (NK cells). As we ana-
lyzed transcripts from PBMCs, this might pertain to both KIR-
expressing NK and T cell subsets. Furthermore, the association
of KIR genes with HVL outcome was mirrored in clinical (sur-
vival time) and functional (decline of blood NK cell numbers,
sustained NK cell proliferation, and loss of NK cell lytic function)
parameters.
How can these associations of KIR genes with SIV disease out-
come be explained? In general, involvement of inhibitory KIR
expressed on cytolytic cells (NK, CD8+ T, γδ T) may lower
the cytolytic activity of these cells toward infected cells (nega-
tive effects), but reduced activity may also result in less immune
pathology (positive effect). Similarly, involvement of activating
KIR proteins may enhance killing of SIV-infected cells by such
cytolytic cells (positive effect), but may also evoke immune pathol-
ogy (negative effect). Thus, beneficial and detrimental effects can
be found for both inhibitory and activating KIR proteins and
presence/absence polymorphisms in the individual’s genotype cer-
tainly influence the outcome. In the case of SIV infection we iden-
tified genes associated with a beneficial (KIR3DL02, KIR3DSW08)
and others with a detrimental (KIR3DL05, KIR3DL10, KIR3DS02)
outcome of infection.
In (uninfected) rhesus macaques, we previously identified KIR
expression on 1–3% of CD4+ T cells, 4–25% of αβ CD8+ T cells,
and 9–58% of γδ T cells (26). The role of KIR expression on T
cell subsets is not as elaborated as for NK cells. It was previously
shown that expression of inhibitory KIR on tumor-infiltrating
human CD8+ T cells was associated with decreased effector func-
tions such as interruption of TCR-mediated signaling and failure
to rearrange the actin cytoskeleton (53). KIR expression is partic-
ularly seen in memory CD8+ T cells, but the exact role of KIR
proteins in the formation of these cells is not known.
As strong linkage disequilibrium of KIR genes can perturb
identification of corresponding risk genes in disease association
studies, we analyzed coincidence of KIR gene transcripts and ana-
lyzed respective correlations. Indeed, KIR3DL05, KIR3DS05, and
KIR3DL10 as well as KIR3DSW08, KIR3DLW03, and KIR3DSW09
correlated, respectively (Table 2). These correlations are most
likely due to underlying haplotypes. Unfortunately, this assump-
tion could not be tested as only a single rhesus macaque KIR
haplotype is completely sequenced (54). Yet, these correlations
complicated the analyses for KIR3DL05–KIR3DS05–KIR3DL10 as
none of these genes show consistent significant associations in all
analyses such as for example KIR3DL02. However, for each of the
various parameters tested at least one member of this KIR gene
cluster shows significant (or borderline significance) association,
indicating that cluster 3DL05–3DS05–3DL10 contains a risk KIR
Table 5 | Known interactions of rhesus macaque KIR and MHC class I
ligands.
KIR Interacting Mamu class I Reference
KIR3DL01 Mamu-B with Bw4 motif (58)
KIR3DLW03 Mamu-A1 alleles *001, *008; *011 (51)
KIR3DL05 Mamu-A1 alleles *001, *002; Mamu-A3*13 (51, 57)
KIR3DL11 Mamu-A1*008 (51)
KIR3DS05 Mamu-A1 alleles *001, *011 (51)
gene. Support for this assumption comes from epistasis analy-
ses of KIR with MHC class I alleles. KIR3DS05 and KIR3DL10
only increased the risk of HVL outcome when Mamu-A1*001 was
absent (odds ratio 21.6), but not when Mamu-A1*001 was present
(odds ratio 1.1). This finding is particularly interesting as Mamu-
A1*001 is a well-known protective MHC class I allotype (55, 56)
and a ligand of KIR3DL05 (51, 57) and KIR3DS05 (51). A sum-
mary of the known KIR and MHC class I interactions is shown
in Table 5. As Mamu-A1*001 is a well-known protective allele, the
observed protective effect in epistasis analysis might also be attrib-
uted to this MHC class I allele only and not to epistasis with KIR
genes. However, this appears rather unlikely given that (1) 35.7%
(10/28) of the HVL animals indeed express Mamu-A1*001 (Table
S2 in Supplementary Material) and are not protected, and (2) the
mere presence of this MHC class I allele does not protect from high
gut viral load (Figure 5A, compare for example 3DS05-/A1*001−
with 3DS05-/A1*001+). Furthermore, statistical epistasis tests do
not become significant because of consistent variant (KIR and
MHC) effects but rather when such variant effects are statistically
not independent (i.e.,not additive for gut viral load). Thus, Mamu-
A1*001 does not have a consistent protective effect across KIR
strata and its effect obviously depends on epistasis with KIR genes.
Further, the combined presence of Mamu-B*012 and KIR3DS05
(OR 10.0, p= 0.087) or KIR3DL10 (OR 25.0, p= 0.036) suggests
a higher risk of HVL outcome. The biological significance of such
epistasis is indicated by significant differences in gastro-intestinal
viral load (Figure 5B) and in significantly shorter survival times
of KIR3DL10-positive animals that lack Mamu-A1*001 or express
Mamu-B*012 (Figure 6). Furthermore, epistasis analyses of HVL
outcome, GIT viral load, and survival times suggest that KIR3DS05
and KIR3DL10 may not be detrimental per se for disease outcome,
but only in combined presence with Mamu-B*012. In accord with
our finding of Mamu-B*012 being a risk factor, this allele was
particularly found on several haplotypes that were associated with
rapid progression to AIDS (30). Some of the limitations of our
analyses that are outlined above might be overcome in future SIV
infection studies involving more animals and when complete KIR
haplotypes are sequenced.
In a previous report Hellmann and colleagues (20) used Mamu-
A1*001-negative SIV-infected rhesus macaques and found that
variations in copy numbers of activating KIR genes associated with
control of SIV replication. Yet, the individual gene(s) underlying
this control were not further specified. In accord with the data of
Hellmann and colleagues, we identified the activating KIR3DSW08
gene (and most likely KIR3DS01 as well) as protective in our
cohort. The identification of the activating KIR3DS05 as a risk
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factor in combination with Mamu-B*12 underscores the necessity
to study associations at the level of individual genes as well as
epistasis of the involved genes.
We conclude that a comprehensive survey of genetic factors that
influence SIV-infection outcome needs both MHC class I and KIR
genes in addition to other known anti-viral factors such as TRIM5.
Such detailed knowledge is important when analyzing respective
data of SIV-infected rhesus macaques to exclude any potential bias
introduced by these disease-relevant genetic factors.
ACKNOWLEDGMENTS
The authors are grateful for expert technical assistance of Nico
Westphal and Ann E. Mayne and thank Dr. Libby Guethlein (Stan-
ford University, Stanford, USA) for providing the rhesus macaque
KIR gene database.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at
http://www.frontiersin.org/journal/10.3389/fimmu.2014.00600/
abstract
REFERENCES
1. Lanier LL. Evolutionary struggles between NK cells and viruses. Nat Rev
Immunol (2008) 8(4):259–68. doi:10.1038/nri2276
2. Chang JJ, Altfeld M. Innate immune activation in primary HIV-1 infection.
J Infect Dis (2010) 202(Suppl 2):S297–301. doi:10.1086/655657
3. Bashirova AA, Thomas R, Carrington M. HLA/KIR restraint of HIV: surviv-
ing the fittest. Annu Rev Immunol (2011) 29:295–317. doi:10.1146/annurev-
immunol-031210-101332
4. Bostik P, Takahashi Y, Mayne AE, Ansari AA. Innate immune natural killer
cells and their role in HIV and SIV infection. HIV Ther (2010) 4:483–504.
doi:10.2217/HIV.10.28
5. Parham P, Abi-Rached L, Matevosyan L, Moesta AK, Norman PJ, Older Aguilar
AM, et al. Primate-specific regulation of natural killer cells. J Med Primatol
(2010) 39:194–212. doi:10.1111/j.1600-0684.2010.00432.x
6. Walter L. Major histocompatibility complex class-I-interacting natural killer
cell receptors of nonhuman primates. J Innate Immunity (2011) 3:236–41.
doi:10.1159/000323932
7. Martin MP, Carrington M. Immunogenetics of HIV disease. Immunol Rev
(2013) 254:245–64. doi:10.1111/imr.12071
8. Martin MP, Gao X, Lee J-H, Nelson GW, Detels R, Goedert JJ, et al. Epistatic
interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat
Genet (2002) 31:429–34. doi:10.1038/ng934
9. Song R, Lisovsky I, Lebouché B, Routy J-P, Bruneau J, Bernard NF. HIV Protec-
tive KIR3DL1/S1-HLA-B genotypes influence NK cell-mediated inhibition of
HIV replication in autologous CD4 targets. PLoS Pathog (2014) 10:e1003867.
doi:10.1371/journal.ppat.1003867
10. Yawata M, Yawata N, Draghi M, Little A-M, Partheniou F, Parham P. Roles for
HLA and KIR polymorphisms in natural killer cell repertoire selection and
modulation of effector function. J Exp Med (2006) 203:633–45. doi:10.1084/
jem.20051884
11. Martin MP, Qi Y, Gao X,Yamada E, Martin JN, Pereyra F, et al. Innate partnership
of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet (2007) 39:733–40.
doi:10.1038/ng2035
12. Alter G, Martin MP, Teigen N, Carr WH, Suscovich TJ, Schneidewind A,
et al. Differential natural killer cell-mediated inhibition of HIV-1 replica-
tion based on distinct KIR/HLA subtypes. J Exp Med (2007) 204:3027–36.
doi:10.1084/jem.20070695
13. Alter G, Rihn S, Walter K, Nolting A, Martin M, Rosenberg ES, et al. HLA
class I subtype-dependent expansion of KIR3DS1+ and KIR3DL1+ NK cells
during acute human immunodeficiency virus type 1 infection. J Virol (2009)
83:6798–805. doi:10.1128/JVI.00256-09
14. Alter G, Heckerman D, Schneidewind A, Fadda L, Kadie CM, Carlson JM,
et al. HIV-1 adaptation to NK-cell-mediated immune pressure. Nature (2011)
476:96–100. doi:10.1038/nature10237
15. Kruse PH, Rosner C, Walter L. Characterization of rhesus macaque KIR geno-
types and haplotypes. Immunogenetics (2010) 62:281–93. doi:10.1007/s00251-
010-0433-4
16. Blokhuis JH, van der Wiel MK, Doxiadis GGM, Bontrop RE. The mosaic
of KIR haplotypes in rhesus macaques. Immunogenetics (2010) 62:295–306.
doi:10.1007/s00251-010-0434-3
17. Blokhuis JH, van der Wiel MK, Doxiadis GGM, Bontrop RE. The extreme plastic-
ity of killer cell Ig-like receptor (KIR) haplotypes differentiates rhesus macaques
from humans. Eur J Immunol (2011) 41:2719–28. doi:10.1002/eji.201141621
18. Moreland AJ, Guethlein LA, Reeves RK, Broman KW, Johnson RP, Parham P,
et al. Characterization of killer immunoglobulin-like receptor genetics and com-
prehensive genotyping by pyrosequencing in rhesus macaques. BMC Genomics
(2011) 12:295. doi:10.1186/1471-2164-12-295
19. Bostik P, Kobkitjaroen J, Tang W, Villinger F, Pereira LE, Little DM, et al.
Decreased NK cell frequency and function is associated with increased risk of
KIR3DL allele polymorphism in simian immunodeficiency virus-infected rhe-
sus macaques with high viral loads. J Immunol (2009) 182:3638–49. doi:10.4049/
jimmunol.0803580
20. Hellmann I, Lim S-Y, Gelman RS, Letvin NL. Association of activating KIR copy
number variation of NK cells with containment of SIV replication in rhesus
monkeys. PLoS Pathog (2011) 7:e1002436. doi:10.1371/journal.ppat.1002436
21. Weatherall D. The Use of Non-human Primates in Research (2006),
pp. 1–153.
22. Mori K,Yasutomi Y, Sawada S,Villinger F, Sugama K, Rosenwith B, et al. Suppres-
sion of acute viremia by short-term postexposure prophylaxis of simian/human
immunodeficiency virus SHIV-RT-infected monkeys with a novel reverse tran-
scriptase inhibitor (GW420867) allows for development of potent antiviral
immune responses resulting in efficient containment of infection. J Virol (2000)
74:5747–53. doi:10.1128/JVI.74.13.5747-5753.2000
23. Villinger F, Brice GT, Mayne AE, Bostik P, Mori K, June CH, et al. Adoptive trans-
fer of simian immunodeficiency virus (SIV) naïve autologous CD4(+) cells to
macaques chronically infected with SIV is sufficient to induce long-term non-
progressor status. Blood (2002) 99:590–9. doi:10.1182/blood.V99.2.590
24. Pereira LE, Johnson RP, Ansari AA. Sooty mangabeys and rhesus macaques
exhibit significant divergent natural killer cell responses during both acute and
chronic phases of SIV infection. Cell Immunol (2008) 254:10–9. doi:10.1016/j.
cellimm.2008.06.006
25. Webster RL, Johnson RP. Delineation of multiple subpopulations of natural
killer cells in rhesus macaques. Immunology (2005) 115:206–14. doi:10.1111/j.
1365-2567.2005.02147.x
26. Hermes M, Albrecht C, Schrod A, Brameier M, Walter L. Expression patterns of
killer cell Immunoglobulin-like receptors (KIR) of NK-cell and T-cell subsets
in old world monkeys. PLoS One (2013) 8:e64936. doi:10.1371/journal.pone.
0064936
27. O’Leary CE, Wiseman RW, Karl JA, Bimber BN, Lank SM, Tuscher JJ, et al. Iden-
tification of novel MHC class I sequences in pig-tailed macaques by amplicon
pyrosequencing and full-length cDNA cloning and sequencing. Immunogenetics
(2009) 61:689–701. doi:10.1007/s00251-009-0397-4
28. Malzahn D, Schillert A, Müller M, Bickeböller H. The longitudinal nonpara-
metric test as a new tool to explore gene-gene and gene-time effects in cohorts.
Genet Epidemiol (2010) 34:469–78. doi:10.1002/gepi.20500
29. Doxiadis GGM, de Groot N, Otting N, de Vos-Rouweler AJM, Bolijn MJ, Hei-
jmans CMC, et al. Haplotype diversity generated by ancient recombination-
like events in the MHC of Indian rhesus macaques. Immunogenetics (2013)
65:569–84. doi:10.1007/s00251-013-0707-8
30. Sauermann U, Siddiqui R, Suh Y-S, Platzer M, Leuchte N, Meyer H, et al.
Mhc class I haplotypes associated with survival time in simian immunodefi-
ciency virus (SIV)-infected rhesus macaques. Genes Immun (2008) 9:69–80.
doi:10.1038/sj.gene.6364448
31. Otting N, Heijmans CMC, Noort RC, de Groot NG, Doxiadis GGM, van Rood
JJ, et al. Unparalleled complexity of the MHC class I region in rhesus macaques.
Proc Natl Acad Sci U S A (2005) 102:1626–31. doi:10.1073/pnas.0409084102
32. Otting N, Heijmans CMC, van der Wiel M, de Groot NG, Doxiadis GGM,
Bontrop RE. A snapshot of the Mamu-B genes and their allelic repertoire
in rhesus macaques of Chinese origin. Immunogenetics (2008) 60:507–14.
doi:10.1007/s00251-008-0311-5
33. Wiseman RW, Karl JA, Bimber BN, O’Leary CE, Lank SM, Tuscher JJ, et al. Major
histocompatibility complex genotyping with massively parallel pyrosequencing.
Nat Med (2009) 15(11):1322–6. doi:10.1038/nm.2038
www.frontiersin.org November 2014 | Volume 5 | Article 600 | 15
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Albrecht et al. KIR/MHC-I polymorphisms in SIV infection
34. Carrington M,Alter G. Innate immune control of HIV. Cold Spring Harb Perspect
Med (2012) 2:a007070. doi:10.1101/cshperspect.a007070
35. Sun JC, Beilke JN, Lanier LL. Adaptive immune features of natural killer cells.
Nature (2009) 457(7229):557–61. doi:10.1038/nature07665
36. Paust S. Andrian von UH. Natural killer cell memory. Nat Immunol (2011)
131:500–8. doi:10.1038/ni.2032
37. Narni-Mancinelli E, Jaeger BN, Bernat C, Fenis A, Kung S, De Gassart A, et al.
Tuning of natural killer cell reactivity by NKp46 and Helios calibrates T cell
responses. Science (2012) 335:344–8. doi:10.1126/science.1215621
38. Waggoner SN, Cornberg M, Selin LK, Welsh RM. Natural killer cells act
as rheostats modulating antiviral T cells. Nature (2012) 481(7381):394–8.
doi:10.1038/nature10624
39. Ebihara T, Jonsson AH, Yokoyama WM. Natural killer cell licensing in mice
with inducible expression of MHC class I. Proc Natl Acad Sci U S A (2013)
110:E4232–7. doi:10.1073/pnas.1318255110
40. Jost S, Altfeld M. Control of human viral infections by natural killer cells.
Annu Rev Immunol (2013) 31:163–94. doi:10.1146/annurev-immunol-032712-
100001
41. Hong HS, Rajakumar PA, Billingsley JM, Reeves RK, Johnson RP. No monkey
business: why studying NK cells in non-human primates pays off. Front Immunol
(2013) 4:32. doi:10.3389/fimmu.2013.00032
42. Naranbhai V, Altfeld M, Karim SSA, Ndung’u T, Karim QA, Carr WH. Changes
in natural killer cell activation and function during primary HIV-1 infection.
PLoS One (2013) 8:e53251. doi:10.1371/journal.pone.0053251
43. Brunetta E, Hudspeth KL, Mavilio D. Pathologic natural killer cell subset redis-
tribution in HIV-1 infection: new insights in pathophysiology and clinical out-
comes. J Leukoc Biol (2010) 88(6):1119–30. doi:10.1189/jlb.0410225
44. Brunetta E, Fogli M, Varchetta S, Bozzo L, Hudspeth KL, Marcenaro E, et al. The
decreased expression of Siglec-7 represents an early marker of dysfunctional
natural killer-cell subsets associated with high levels of HIV-1 viremia. Blood
(2009) 114:3822–30. doi:10.1182/blood-2009-06-226332
45. LaBonte ML, McKay PF, Letvin NL. Evidence of NK cell dysfunction in SIV-
infected rhesus monkeys: impairment of cytokine secretion and NKG2C/C2
expression. Eur J Immunol (2006) 36:2424–33. doi:10.1002/eji.200635901
46. Lang PA, Lang KS, Xu HC, Grusdat M, Parish IA, Recher M, et al. Natural killer
cell activation enhances immune pathology and promotes chronic infection by
limiting CD8+ T-cell immunity. Proc Natl Acad Sci U S A (2012) 109(4):1210–5.
doi:10.1073/pnas.1118834109
47. Welsh RM, Waggoner SN. NK cells controlling virus-specific T cells: rheostats
for acute vs. persistent infections. Virology (2013) 435:37–45. doi:10.1016/j.virol.
2012.10.005
48. Choi EI, Reimann KA, Letvin NL. In vivo natural killer cell depletion during
primary simian immunodeficiency virus infection in rhesus monkeys. J Virol
(2008) 82:6758–61. doi:10.1128/JVI.02277-07
49. Reeves RK, Rajakumar PA, Evans TI, Connole M, Gillis J, Wong FE, et al. Gut
inflammation and indoleamine deoxygenase inhibit IL-17 production and pro-
mote cytotoxic potential in NKp44+ mucosal NK cells during SIV infection.
Blood (2011) 118:3321–30. doi:10.1182/blood-2011-04-347260
50. Liyanage NPM, Gordon SN, Doster MN, Pegu P, Vaccari M, Shukur N, et al.
Antiretroviral therapy partly reverses the systemic and mucosal distribution of
NK cell subsets that is altered by SIVmac251 infection of macaques. Virology
(2014) 45(0–451):359–68. doi:10.1016/j.virol.2013.12.003
51. Rosner C, Kruse PH, Hermes M, Otto N, Walter L. Rhesus macaque inhibitory
and activating KIR3D interact with Mamu-A-encoded ligands. J Immunol
(2011) 186:2156–63. doi:10.4049/jimmunol.1002634
52. Mühl T, Krawczak M, Haaft ten P, Hunsmann G, Sauermann U. MHC class
I alleles influence set-point viral load and survival time in simian immun-
odeficiency virus-infected rhesus monkeys. J Immunol (2002) 169:3438–46.
doi:10.4049/jimmunol.169.6.3438
53. Guerra N, Michel F, Gati A, Gaudin C, Mishal Z, Escudier B, et al. Engage-
ment of the inhibitory receptor CD158a interrupts TCR signaling, preventing
dynamic membrane reorganization in CTL/tumor cell interaction. Blood (2002)
100:2874–81. doi:10.1182/blood-2002-02-0643
54. Sambrook JG, Bashirova A, Palmer S, Sims S, Trowsdale J, Abi-Rached L,
et al. Single haplotype analysis demonstrates rapid evolution of the killer
immunoglobulin-like receptor (KIR) loci in primates. Genome Res (2005)
15:25–35. doi:10.1101/gr.2381205
55. Zhang Z-Q, Fu T-M, Casimiro DR, Davies M-E, Liang X, Schleif WA, et al.
Mamu-A*01 allele-mediated attenuation of disease progression in simian-
human immunodeficiency virus infection. J Virol (2002) 76:12845–54. doi:10.
1128/JVI.76.24.12845-12854.2002
56. Mothé BR, Weinfurter J, Wang C, Rehrauer W, Wilson N, Allen TM, et al. Expres-
sion of the major histocompatibility complex class I molecule Mamu-A*01 is
associated with control of simian immunodeficiency virus SIVmac239 replica-
tion. J Virol (2003) 77:2736–40. doi:10.1128/JVI.77.4.2736-2740.2003
57. Colantonio AD, Bimber BN, Neidermyer WJ, Reeves RK, Alter G, Altfeld M,
et al. Polymorphisms modulate peptide-dependent binding to an MHC Class I
ligand with a Bw6 Motif. PLoS Pathog (2011) 7:e1001316. doi:10.1371/journal.
ppat.1001316
58. Schafer JL, Colantonio AD, Neidermyer WJ, Dudley DM, Connole M, O’Connor
DH, et al. KIR3DL01 recognition of Bw4 ligands in the rhesus macaque: main-
tenance of Bw4 specificity since the divergence of apes and old world monkeys.
J Immunol (2014) 192:1907–17. doi:10.4049/jimmunol.1302883
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 03 October 2014; accepted: 07 November 2014; published online: 28 November
2014.
Citation: Albrecht C, Malzahn D, Brameier M, Hermes M, Ansari AA and Walter L
(2014) Progression to AIDS in SIV-infected rhesus macaques is associated with distinct
KIR and MHC class I polymorphisms and NK cell dysfunction. Front. Immunol. 5:600.
doi: 10.3389/fimmu.2014.00600
This article was submitted to NK Cell Biology, a section of the journal Frontiers in
Immunology.
Copyright © 2014 Albrecht , Malzahn, Brameier , Hermes, Ansari and Walter . This is
an open-access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) or licensor are credited and that the original publica-
tion in this journal is cited, in accordance with accepted academic practice. No use,
distribution or reproduction is permitted which does not comply with these terms.
Frontiers in Immunology | NK Cell Biology November 2014 | Volume 5 | Article 600 | 16
